Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLA 15

Drug Profile

VLA 15

Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; Lyme-borreliosis-vaccine-Valneva; Lyme-disease-vaccine-GlaxoSmithKline/Valneva; Lyme-disease-vaccine-Valneva; VLA 15

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Bacterial vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Lyme disease

Most Recent Events

  • 30 Sep 2019 Valneva completes enrolment in its phase II trial for Lyme disease in USA and Europe
  • 01 Jul 2019 Valneva initiates a phase II clinical trials in Lyme disease (Prevention) in USA (IM) (NCT03970733)
  • 20 Jun 2019 Valneva and GlaxoSmithKline ended the strategic alliance agreement of research and development assets including VLA15
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top